<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03325140</url>
  </required_header>
  <id_info>
    <org_study_id>RE-CCIP (29BRC17.0157)</org_study_id>
    <nct_id>NCT03325140</nct_id>
  </id_info>
  <brief_title>Platelet Transfusions in Critically Ill Patient</brief_title>
  <acronym>RE-CCIP</acronym>
  <official_title>Platelet Transfusion Efficacy in Critically Ill Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Brest</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Between 10 and 15% of critically ill patients require platelet transfusion within their
      intensive care unit (ICU).

      Platelets (PLT) are given to prevent bleeding in thrombocytopenic patients or to treat
      bleeding as part of massive transfusion or in bleeding thrombocytopenic patients.

      International and local guidelines (American Association of Blood Banks-AABB) are mainly
      based on experts' opinion. The efficacy of PLT transfusion in the ICU setting remains poorly
      studied and unknown and the administration of PLT may be associated with adverse effects
      including an increased risk of hospital acquired infection. Finally, the short PLT
      shelve-life may be responsible for inventory issues. Altogether, this makes very important to
      improve the evidence that support PLT transfusion in ICU patients.

      This is a multicentre prospective observational study that aims to first determine PLT
      transfusion efficacy and to identify the parameters associated with transfusion efficacy and
      to analyse the compliance with international (and local) guidelines of PLT transfusion in ICU
      patients.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2018</start_date>
  <completion_date type="Anticipated">September 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>platelet transfusion efficacy</measure>
    <time_frame>between 18 hours and 28 days after transfusion</time_frame>
    <description>corrected count platelet increment</description>
  </primary_outcome>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Platelet Transfusion</condition>
  <condition>Critical Illness</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients admitted to intensive care and receiving platelet transfusion whatever the reason
        for it.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients admitted to intensive care and receiving at least one platelet transfusion in
             intensive care unit

        Exclusion Criteria:

          -  Age less than 18
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>AUBRON Cécile</last_name>
    <phone>+33 2 98 34 78 59</phone>
    <email>cecile.aubron@chu-brest.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU d'Angers</name>
      <address>
        <city>Angers</city>
        <zip>49100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Brest</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aubron Cécile</last_name>
      <email>cecile.aubron@chu-brest.fr</email>
    </contact>
    <investigator>
      <last_name>Olivier Huet, Pr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>LE MEUR Anthony</last_name>
      <email>anthony.lemeur@chu-nantes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>SEGUIN Philippe</last_name>
      <email>philippe.seguin@chu-brest.fr</email>
    </contact>
    <investigator>
      <last_name>TADIE Jean-Marc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>EHRMANN Stephan</last_name>
      <email>stephan.ehrmann@chu-tours.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2017</study_first_submitted>
  <study_first_submitted_qc>October 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2017</study_first_posted>
  <last_update_submitted>February 26, 2018</last_update_submitted>
  <last_update_submitted_qc>February 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

